Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 3/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897802 | 1.00 | PPARA (0.67) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL30836085 | 1.00 | PPARA (0.67) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL2890895 | 0.89 | JAK3 (0.60) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL2890892 | 0.89 | JAK3 (0.60) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL6557659 | 0.86 | JAK3 (0.61) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL1204211 | 0.86 | JAK3 (0.61) | PPARACTSSPPARGJAK3BTK | |
| SCHEMBL2948481 | 0.84 | PPARA (0.74) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL5249102 | 0.84 | PPARA (0.74) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL2948482 | 0.84 | PPARA (0.74) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL1132901 | 0.84 | PPARA (0.90) | PPARACTSSPPARGRAB9AKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820680-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080261923-A1 | Alkene Mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-23 | — | — | US | disclosed |
| US-20080009490-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261923-A1 | Alkene Mimics | PHOSPHO1, PARN, CHAMP1 | PPARA 2016/4885CTSS 2059/4885PPARG 2738/4885 |
| US-20080009490-A1 | Hiv Integrase Inhibitors | TYMS, UNG, TYMP | PPARA 4759/4885CTSS 1861/4885PPARG 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.